Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.81 |
| ▸ | DPP8 | Q6V1X1 | 17/20 | 0.81 |
| ▸ | DPP9 | Q86TI2 | 17/20 | 0.81 |
| ▸ | DPP7 | Q9UHL4 | 17/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.62 |
| ▸ | FAP | Q12884 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216321 | 1.00 | DPP4 (0.81) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL14282813 | 0.90 | DPP4 (1.00) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL14282811 | 0.88 | DPP4 (1.00) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL8289115 | 0.87 | DPP4 (1.00) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL8216566 | 0.82 | DPP4 (0.71) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL14282823 | 0.82 | DPP4 (0.74) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL14220607 | 0.82 | DPP4 (0.71) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL8216396 | 0.82 | DPP4 (0.71) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL8220719 | 0.80 | DPP4 (0.76) | DPP4DPP8DPP9DPP7CYP2D6 | |
| SCHEMBL8218895 | 0.79 | DPP4 (0.69) | DPP4DPP8DPP9DPP7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905759-A1 | N-[1-(3-AMINO-4-PHENYL-BUTYRYL)-4-HYDROXY-PYRROLIDIN-2-YLMETHYL}-PROPIONAMIDE AND RELATED COMPOUNDS AS DPP-IV INHIBITORS FOR THE TREATMENT OFTYPE 2 DIABETES MELLITUS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008028662-A1 | N-[1-(3-AMINO-4-PHENYL-BUTYRYL)-4-HYDROXY-PYRROLIDIN-2-YLMETHYL}-PROPIONAMIDE AND RELATED COMPOUNDS AS DPP-IV INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | WO | disclosed |